Renalis Named to 2022 CB Insights Digital Health 150
CLEVELAND, OH., Dec. 12, 2022 -- Renalis, a digital health company for pelvic health disorders, today announced that it was named to the 2022 CB Insights Digital Health 150 list. This is the first year that Renalis has been included in the list of 150 of the most promising, private digital healthcare companies in the world. The prestigious annual ranking selects 150 winners from over thirteen thousand private companies transforming healthcare with digital technology.
Companies named to the Digital Health 150 List are chosen based on a range of factors including data, proprietary scores, company business models, funding, investor profile, momentum in the market, and other criteria.
Renalis treats chronic, expensive, and stigmatized conditions below the belt (pelvic health disorders) in females+ with easy-to-use, clinically-proven digital therapeutics. By doing so, Renalis solves a void in the market for accessible solutions for first-line therapy for the 33 million+ people struggling with these disorders. Renalis’ novel platform removes barriers to equity and access to treatment; saving providers & patients time, improving outcomes, and reducing healthcare costs.
“We are honored that Renalis’ innovation in pelvic healthcare has been recognized by CB Insights,” said Missy Lavender, Co-founder & CEO of Renalis. “Our platform of digital therapeutics to treat conditions such as overactive bladder or urinary incontinence will be a game-changer for providers and patients alike. Renalis is committed to impacting patient care in a meaningful way by providing digital tools that solve important clinical problems."
About Renalis
Renalis has a platform of clinically proven digital therapeutics to treat chronic, expensive and stigmatized conditions below the belt (pelvic health disorders), beginning first with women and persons assigned female. with easy to use, clinically-proven digital therapeutics. Renalis removes barriers to equity and access to treatment, saving providers & patients time, improving outcomes and reducing healthcare costs. Renalis has successfully completed a Proof-of-Concept study with University Hospitals (UH; Case Western) and an FDA pre-submission meeting for its first commercial product and has launched its second, broader bladder health product in a pilot study, also with UH. Renalis is a Cleveland-based, Delaware C-Corp.
For more information visit www.Renalishealth.com.
About CB Insights
CB Insights builds software that enables the world's best companies to discover, understand, and make technology decisions with confidence. By marrying data, expert insights, and work management tools, clients manage their end-to-end technology decision-making process on CB Insights. To learn more, please visit www.cbinsights.com.
Renalis Media Contact
Missy Lavender
missy@renalis.health
312.287.1951